



April 6, 2020

Acenxion Biosystems announces exclusive patent license

[Kansas City, KS] Acenxion Biosystems today announced the successful execution of an exclusive patent and related IP licensing agreement with the University of Missouri (UM).

Included in the license is exclusive access to:

- U.S. Patent No. 8,635,028 titled “Rapid Detection of Viable Bacterial System and Method”
- U.S. Patent No. 10,273,522 titled “Rapid Detection of Viable Bacterial System and Method”
- U.S. Patent Application No. 16/397/932 titled “Rapid Detection of Viable Bacterial System and Method”
- P.C.T. Patent Application No. US2019/01950 titled “Detection of Living Cells”
- U.S. Patent Application No. 16/285,891 titled “Detection of Living Cells”

Acenxion Biosystems (ACXBIO) is a privately funded company developing automated systems for bacteria detection in blood cultures and phenotypic antimicrobial susceptibility testing (AST). Seamlessly fitting into current clinical workflows, Acenxion’s scalable AST system reduces the time required for phenotypic testing to just 4-6 hours allowing clinicians rapid use of a precise, targeted treatment. Acenxion’s technology improves patient outcomes, reduces healthcare costs, and reduces the spread of antibiotic resistance extending the service life of antibiotics.